VERIPHARM
ActiveSummary
VERIPHARM has been active since 2001 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €885,230 and a net result of €184,855, of which €164,087 non-recurring income. Equity is growing by about 3.1% per year across the filed financial years. Its solvency ranks better than 63% of 2,802 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Articles of association
What the company does
- Name clauseThe name the company operates under according to its articles.
- VERIPHARM
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaams Gewest” (deed in Dutch)“St.-Jozefslaan 55,2400 Mol” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Enige bestuurder of meerdere bestuurders” (deed in Dutch)“Enige bestuurder, niet persoonlijk gehouden tot verbintenissen van vennootschap” (deed in Dutch)“Zes jaar, raad van bestuur” (deed in Dutch)“Kennisgeving aan raad van bestuur, verplicht opdracht te vervullen tot vervanging binnen redelijke termijn” (deed in Dutch)“Plaats openvalt vóór einde mandaat, eerstvolgende algemene vergadering” (deed in Dutch)“Enige bestuurder, geheel bestuursbevoegdheden” (deed in Dutch)1 more provision on this in the deed
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- 25 June at 20:00
Oversight and winding up
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Benoeming vereffenaars, ontbinding om welke reden en op welk ogenblik ook” (deed in Dutch)“Alle verrichtingen vermeld in wet, bevoegdheden vereffenaars” (deed in Dutch)